193 related articles for article (PubMed ID: 29865878)
1. A patent review of immunoproteasome inhibitors.
Ogorevc E; Schiffrer ES; Sosič I; Gobec S
Expert Opin Ther Pat; 2018 Jul; 28(7):517-540. PubMed ID: 29865878
[TBL] [Abstract][Full Text] [Related]
2. Immunoproteasome-selective and non-selective inhibitors: A promising approach for the treatment of multiple myeloma.
Ettari R; Zappalà M; Grasso S; Musolino C; Innao V; Allegra A
Pharmacol Ther; 2018 Feb; 182():176-192. PubMed ID: 28911826
[TBL] [Abstract][Full Text] [Related]
3. Immunoproteasome-selective inhibitors: An overview of recent developments as potential drugs for hematologic malignancies and autoimmune diseases.
Xi J; Zhuang R; Kong L; He R; Zhu H; Zhang J
Eur J Med Chem; 2019 Nov; 182():111646. PubMed ID: 31521028
[TBL] [Abstract][Full Text] [Related]
4. A Nut for Every Bolt: Subunit-Selective Inhibitors of the Immunoproteasome and Their Therapeutic Potential.
Huber EM; Groll M
Cells; 2021 Jul; 10(8):. PubMed ID: 34440698
[TBL] [Abstract][Full Text] [Related]
5. Role of Epoxide Hydrolases and Cytochrome P450s on Metabolism of KZR-616, a First-in-Class Selective Inhibitor of the Immunoproteasome.
Fang Y; Johnson H; Anderl JL; Muchamuel T; McMinn D; Morisseau C; Hammock BD; Kirk C; Wang J
Drug Metab Dispos; 2021 Sep; 49(9):810-821. PubMed ID: 34234005
[TBL] [Abstract][Full Text] [Related]
6. Immunoproteasome Activity and Content Determine Hematopoietic Cell Sensitivity to ONX-0914 and to the Infection of Cells with Lentiviruses.
Vagapova E; Burov A; Spasskaya D; Lebedev T; Astakhova T; Spirin P; Prassolov V; Karpov V; Morozov A
Cells; 2021 May; 10(5):. PubMed ID: 34066177
[TBL] [Abstract][Full Text] [Related]
7. Immunoproteasome-selective inhibitors: the future of autoimmune diseases?
Zhang C; Zhu H; Shao J; He R; Xi J; Zhuang R; Zhang J
Future Med Chem; 2020 Feb; 12(4):269-272. PubMed ID: 31983229
[No Abstract] [Full Text] [Related]
8. On the role of the immunoproteasome in transplant rejection.
Basler M; Li J; Groettrup M
Immunogenetics; 2019 Mar; 71(3):263-271. PubMed ID: 30220008
[TBL] [Abstract][Full Text] [Related]
9. The immunoproteasome: a novel drug target for autoimmune diseases.
Basler M; Mundt S; Bitzer A; Schmidt C; Groettrup M
Clin Exp Rheumatol; 2015; 33(4 Suppl 92):S74-9. PubMed ID: 26458097
[TBL] [Abstract][Full Text] [Related]
10. Immunoproteasome inhibition prevents chronic antibody-mediated allograft rejection in renal transplantation.
Li J; Basler M; Alvarez G; Brunner T; Kirk CJ; Groettrup M
Kidney Int; 2018 Mar; 93(3):670-680. PubMed ID: 29229189
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and Biochemical Evaluation of Warhead-Decorated Psoralens as (Immuno)Proteasome Inhibitors.
Schiffrer ES; Proj M; Gobec M; Rejc L; Šterman A; Mravljak J; Gobec S; Sosič I
Molecules; 2021 Jan; 26(2):. PubMed ID: 33445542
[TBL] [Abstract][Full Text] [Related]
12. Inhibitors of the immunoproteasome: current status and future directions.
Miller Z; Ao L; Kim KB; Lee W
Curr Pharm Des; 2013; 19(22):4140-51. PubMed ID: 23181576
[TBL] [Abstract][Full Text] [Related]
13. Co-inhibition of immunoproteasome subunits LMP2 and LMP7 is required to block autoimmunity.
Basler M; Lindstrom MM; LaStant JJ; Bradshaw JM; Owens TD; Schmidt C; Maurits E; Tsu C; Overkleeft HS; Kirk CJ; Langrish CL; Groettrup M
EMBO Rep; 2018 Dec; 19(12):. PubMed ID: 30279279
[TBL] [Abstract][Full Text] [Related]
14. Selective immunoproteasome inhibitors with non-peptide scaffolds identified from structure-based virtual screening.
Kasam V; Lee NR; Kim KB; Zhan CG
Bioorg Med Chem Lett; 2014 Aug; 24(15):3614-7. PubMed ID: 24913713
[TBL] [Abstract][Full Text] [Related]
15. Discovery and Early Clinical Development of Selective Immunoproteasome Inhibitors.
Kirk CJ; Muchamuel T; Wang J; Fan RA
Cells; 2021 Dec; 11(1):. PubMed ID: 35011570
[TBL] [Abstract][Full Text] [Related]
16. Immunoproteasome Inhibition Selectively Kills Human CD14
Basler M; Claus M; Klawitter M; Goebel H; Groettrup M
J Immunol; 2019 Oct; 203(7):1776-1785. PubMed ID: 31484727
[TBL] [Abstract][Full Text] [Related]
17. Immunoproteasome Function in Normal and Malignant Hematopoiesis.
Tubío-Santamaría N; Ebstein F; Heidel FH; Krüger E
Cells; 2021 Jun; 10(7):. PubMed ID: 34206607
[TBL] [Abstract][Full Text] [Related]
18. Design and Evaluation of Highly Selective Human Immunoproteasome Inhibitors Reveal a Compensatory Process That Preserves Immune Cell Viability.
Ladi E; Everett C; Stivala CE; Daniels BE; Durk MR; Harris SF; Huestis MP; Purkey HE; Staben ST; Augustin M; Blaesse M; Steinbacher S; Eidenschenk C; Pappu R; Siu M
J Med Chem; 2019 Aug; 62(15):7032-7041. PubMed ID: 31283222
[TBL] [Abstract][Full Text] [Related]
19. Mitigated viral myocarditis in A/J mice by the immunoproteasome inhibitor ONX 0914 depends on inhibition of systemic inflammatory responses in CoxsackievirusB3 infection.
Goetzke CC; Althof N; Neumaier HL; Heuser A; Kaya Z; Kespohl M; Klingel K; Beling A
Basic Res Cardiol; 2021 Feb; 116(1):7. PubMed ID: 33523326
[TBL] [Abstract][Full Text] [Related]
20. Immunoproteasome Inhibition Impairs T and B Cell Activation by Restraining ERK Signaling and Proteostasis.
Schmidt C; Berger T; Groettrup M; Basler M
Front Immunol; 2018; 9():2386. PubMed ID: 30416500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
